Fwd: Price Increase of the EMBO Journal for 2004 (Open letter to Prof Frank Gannon)

[kaemper _at__ ub.uni-stuttgart.de]

[Die folgende e-mail von David Prosser, Director SPARC Europe, leite 
ich hiermit weiter an erwerb-l, mit cc an inetbib, medibib-l, ezb. 
Mehrfachempfang bitte ich zu entschuldigen. MfG, B.-C. Kaemper, UB
Stuttgart]

-----Original Message-----
Date: Mon, 5 Jan 2004 13:28:46 -0000
From: "David Prosser" <david.prosser _at__ bodley.ox.ac.uk>

Dear All

You may be interested to see the e-mail below that we have just sent to
Frank Gannon, Executive Director of EMBO.  Many of you will have seen a
massive increase in the cost of subscribing to The EMBO Journal in 2004
and the open letter is intended to bring home to Professor Gannon the
problems that this will bring to the library community.

A list of editorial board members for THE EMBO Journal is given at:

http://www3.oup.co.uk/jnls/list/embojo/edboards/

If you feel that this price rise is unacceptable, you may wish to check
whether any of the Board members are at your institution and raise the
issue of the price with them!

Happy New Year

David

David C Prosser PhD
Director
SPARC Europe

E-mail:  david.prosser _at__ bodley.ox.ac.uk
Tel:       +44 (0) 1865 284 451
Mobile:  +44 (0) 7974 673 888
http://www.sparceurope.org


-----Original Message-----
From: David Prosser [mailto:david.prosser _at__ bodley.ox.ac.uk] 
Sent: 05 January 2004 13:18
To: 'Frank.Gannon _at__ embo.org'
Cc: SPARC-EUROPE _at__ JISCMAIL.AC.UK; 'nurse _at__ rockefeller.edu';
'christiane.nuesslein-volhard _at__ tuebingen.mpg.de';
'cesare _at__ civ.bio.unipd.it'
Subject: Price Increase of the EMBO Journal for 2004

An open letter to Professor Frank Gannon on behalf of the International
Research Library Community


Dear Professor Gannon

I am writing to you to expresses the dismay of the international
research library community at the extreme rise in price for The EMBO
Journal in 2004.  The decisions to bundle The EMBO Journal and EMBO
Reports into one ?take it or leave it? package and to move to a
?full-time equivalents? pricing model means that many libraries are
facing a doubling of the price of The EMBO Journal in 2004, at a time
when throughout Europe and in the US we are working with reduced library
budgets.

While there is no doubt that The EMBO Journal is one of the world?s
leading titles, it is inevitable that a price rise of this magnitude
will result in fewer libraries being able to subscribe, so narrowing the
dissemination of the research published in the journal and consequently
decreasing the impact of each paper published.  It is hard to see how
this can be in the interests of either the journal?s authors or
readers.  We also recognise that profits from The EMBO Journal are used
to benefit the molecular biology community.  However, there must be a
balance struck between these benefits and the ability of libraries to
afford to purchase the journal.  A price rise of 100% shifts
the balance too far to profit maximisation.

It is ironic that EMBO should choose to impose such an increase (far in
excess of what we have been used to even from commercial publishers) at
the time when many are looking to new financial models to support
scholarly communications.  Many publishers are either launching new open
access journals (e.g., BioMedCentral, the Public Library of Science) or
attempting to convert existing journals to
open access (e.g., the Company of Biologists, the American Physiological
Society).  Funding bodies are becoming increasingly supportive of open
access with major statements coming in recent months from the German
funding agents, the Wellcome Trust in the UK, and the Howard Hughes in
the US.

Publication in open access journals gives authors wider dissemination of
their research and greater impact. EMBO could, considering both its
position at the heart of European molecular biology and the reputation
and standing of The EMBO Journal, be at the forefront of open access,
bringing great benefits to authors, readers, and molecular biology in
general.  Instead, the new pricing policy will reduce access to The EMBO
Journal and restrict the free flow of scholarly information.  We
therefore call on EMBO to reconsider this excessive and damaging price
rise.

Yours sincerely


Bas Savenije
Chair, SPARC Europe

http://www.sparceurope.org/